Inicio>>Signaling Pathways>> Cell Cycle/Checkpoint>> PAK>>AZ13705339 hemihydrate

AZ13705339 hemihydrate

Catalog No.GC66036

El hemihidrato de AZ13705339 es un inhibidor de PAK1 muy potente y selectivo con IC50 de 0,33 nM y 59 nM para PAK1 y pPAK1, respectivamente. El hemihidrato de AZ13705339 tiene afinidades de uniÓn a PAK1 y PAK2, con Kds de 0,28 nM y 0,32 nM, respectivamente. El hemihidrato AZ13705339 se puede utilizar en la investigaciÓn de cÁnceres.

Products are for research use only. Not for human use. We do not sell to patients.

AZ13705339 hemihydrate Chemical Structure

Tamaño Precio Disponibilidad Cantidad
10mg
225,00 $
Disponible
25mg
495,00 $
Disponible
50mg
765,00 $
Disponible
100mg
1.215,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

AZ13705339 hemihydrate is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 hemihydrate has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 hemihydrate can be used in the research of cancers[1].

AZ13705339 (1 μM) hemihydrate inhibits αIgM-controlled adhesion and not PMA-induced adhesion in Namalwa cells[2].
AZ13705339 (300 nM, 30 min) prevents Siglec-8 engagement-induced eosinophil death[3].

AZ13705339 hemihydrate (100 mg/kg, P.O.) has moderate clearance and oral Cmax of 7.7 μM in rats[1].

Reseñas

Review for AZ13705339 hemihydrate

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AZ13705339 hemihydrate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.